#oral medication

Structure Therapeuticsは、その経口GLP-1受容体作動薬の励みになる第2相の結果を報告し、注射剤型の減量および糖尿病薬の代替丸剤形式を推し進めています。

After years of development challenges, oral GLP-1 weight loss drugs are finally hitting the market. Novo Nordisk's oral Wegovy is already available, with Eli Lilly's orforglipron expected to win FDA approval soon.

Novo Nordisk has struck a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral versions of obesity and diabetes treatments. The partnership could eliminate the need for weekly injections that have defined the GLP-1 drug revolution.